Multicenter retrospective study of clinical, endoscopic and pathological characteristics of autoimmune gastritis

Multicenter retrospective study of clinical, endoscopic and pathological characteristics of autoimmune gastritis - Multicenter retrospective study of AIG

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033785

Enrollment

250

Registered

2018-08-18

Start date

2018-08-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune gastritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who were diagnosed as having AIG according to the following tentative criteria. 1)Corpus dominant atrophy on endoscopy 2) Positivity for anti-parietal cell antibody or anti-intrinsic factor antibody 3) Serum gastrin level > 350 pg/ml

Exclusion criteria

Exclusion criteria: The patients who were prescribed proton pomp inhibitor or vonoprazan fumarate and the patients who underwent gastrectomy or had renal failure.

Design outcomes

Primary

Measure	Time frame
1) Endoscopic findings: Kyoto gastritis classification and other findings like remnant oxyntic mucosa, status of antrum, mucous condition. Findings through indigo carmine dying method or NBI magnifying method. 2) Histological findings of each biopsy site, number of biopsies. 3) Blood sample results: titer of anti-parietal cell antibody, existence of anti-intrinsic factor antibody, PG1, PG 2, PG 1/2, RBC, Hb, Ht, MCV, WBC, platelet, VB12, folic acid, Fe, TSH, anti-thyroglobulin antibody, anti-glutamic acid decarboxylase antibody, blood sugar, HbA1C and others presumed to be related AIG. 4) Helicobacter pylori infection associated data :13C-UBT, anti H. pylori IgG antibody and H. pylori stool antigen. 5) Other associated clinical information, if available.	—

Measure

Time frame

1) Endoscopic findings: Kyoto gastritis classification and other findings like remnant oxyntic mucosa, status of antrum, mucous condition. Findings through indigo carmine dying method or NBI magnifying method. 2) Histological findings of each biopsy site, number of biopsies. 3) Blood sample results: titer of anti-parietal cell antibody, existence of anti-intrinsic factor antibody, PG1, PG 2, PG 1/2, RBC, Hb, Ht, MCV, WBC, platelet, VB12, folic acid, Fe, TSH, anti-thyroglobulin antibody, anti-glutamic acid decarboxylase antibody, blood sugar, HbA1C and others presumed to be related AIG. 4) Helicobacter pylori infection associated data :13C-UBT, anti H. pylori IgG antibody and H. pylori stool antigen. 5) Other associated clinical information, if available.

—

Countries

Japan

Contacts

Public ContactNoriko Kakinoki

Kakogawa Central City Hospital Clinical study and trial center

n-kakinoki@kakohp.jp079-451-5500

Outcome results